Denali Therapeutics Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Ryan J. Watts
- Full Time Employees
- 503
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 161 Oyster Point Boulevard South San Francisco CA United States of America 94080
- IPO Date
- Dec 8, 2017
- CIK
- 0001714899
- Website
- denalitherapeutics.com
- Similar Companies
- Business
- Denali Therapeutics Inc. (NASDAQ: DNLI) develops therapies for neurodegenerative and lysosomal storage diseases. The company focuses on programs targeting Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), and mucopolysaccharidosis type IIIA (MPS IIIA), including DNL343 for ALS and frontotemporal dementia, DNL788 for ALS and Parkinson's, tividenofusp alfa for MPS IIIA, and buntanetap for Alzheimer's; it also advances discovery efforts in other rare diseases. Founded in 2015 and headquartered in South San Francisco, California, Denali operates primarily in the United States with a pipeline built on its proprietary Engineered Antibody Transport (ATLAS) and Enzyme Transport Vehicle (ETV) technologies for crossing the blood-brain barrier. Denali Therapeutics serves the biopharmaceutical industry, targeting patients with neurodegenerative disorders through clinical-stage assets and research collaborations. Its geographic operations center in the U.S., with global partnerships extending research impact. The company maintains subsidiaries like Denali Medtech Inc. for manufacturing support.
Company News
BlackRock Inc. Takes Position in Denali Therapeutics Inc. $DNLI
DNLI Stock Gains 33.1% in Three Months: Buy, Sell or Hold the Stock?
Denali Therapeutics: Bullish On Avlayah And Their Prospects
Head to Head Comparison: Denali Therapeutics (NASDAQ:DNLI) versus Humacyte (NASDAQ:HUMA)
Denali Therapeutics: AVLAYAH Converts A Platform Story Into A Commercial One
Baillie Gifford Trims Denali Therapeutics (DNLI) Stake in June Reduction
Denali Therapeutics Inc. $DNLI Shares Acquired by California State Teachers Retirement System
DNLI Q2 Loss Narrows, Avlayah Sales Drive Strong Launch Momentum
Denali Therapeutics Inc. (DNLI) Q2 2026 Earnings Call Transcript
Denali Therapeutics Q2 Earnings Call Highlights
Denali Therapeutics Inc. (DNLI) Reports Q2 Loss, Tops Revenue Estimates
Denali Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights
Denali Therapeutics to Report Second Quarter 2026 Financial Results and Business Highlights on August 6, 2026
Will Recent Setbacks Impact Growth Prospects of DNLI Stock?
Denali Therapeutics to Give Opening Plenary Address at Alzheimer's Association International Conference (AAIC) 2026 and Highlight Breakthroughs in Delivering Biologic Therapies Across Blood-Brain Barrier
DNLI Stock Surges 59.4% Year to Date: Is There More Room for Growth?
Denali to Sell Priority Review Voucher for $195M Cash Boost
Denali Therapeutics Enters Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $195 Million
Denali Therapeutics Inc. (DNLI) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Denali Therapeutics: 'Strong Buy' On AVLAYAH Approval And End Of 2026 FTD-GRN Data